Daytrana Duration-Of-Use Data Suggest Potential For Individualized Dosing
This article was originally published in The Pink Sheet Daily
Phase IIIb study of methylphenidate patch shows efficacy when used for four- and six-hour periods, Shire says.
You may also be interested in...
The transdermal methylphenidate patch is approved with one additional warning relating to skin reactions and possible sensitivity to oral methylphenidate products.
Roche will consider requesting a re-examination of the negative decision by the Committee for Medicinal Products for Human Use.
A Phase III trial will compare 40 mg/day glatiramer to the 20 mg/day approved dose.